About Pharmerit_WPadmin

This author has not yet filled in any details.
So far Pharmerit_WPadmin has created 292 blog entries.

Together We Stand

We stand behind our diverse, inclusive, and equitable culture. We demand equality, opportunity, and justice for all. We accept our responsibility to educate, advocate, and foster community within and outside of our company.

2020-06-02T12:46:56-04:00June 2nd, 2020|

Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong

Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong Background Direct-acting antivirals (DAAs) are entering the hepatitis C virus (HCV) [...]

2020-05-12T07:25:29-04:00May 11th, 2020|

Machine Learning for Precision Health Economics and Outcomes Research (P-HEOR): Conceptual Review of Applications and Next Steps

Machine Learning for Precision Health Economics and Outcomes Research (P-HEOR): Conceptual Review of Applications and Next Steps Abstract Precision health economics and outcomes research (P-HEOR) integrates economic and clinical value assessment [...]

2020-05-08T04:00:12-04:00May 8th, 2020|

Modified Delphi Study of Decision-Making Around Treatment Sequencing in Relapsing-Remitting Multiple Sclerosis

Modified Delphi Study of Decision-Making Around Treatment Sequencing in Relapsing-Remitting Multiple Sclerosis Background Existing effectiveness models of disease-modifying drugs (DMDs) for relapsing-remitting multiple sclerosis (RRMS) evaluate a single line of [...]

2020-04-20T09:02:51-04:00April 20th, 2020|

Cost-effectiveness of alternative strategies for vaccination of adolescents against serogroup B IMD with the MenB-FHbp vaccine in Canada

Cost-effectiveness of Alternative Strategies for Vaccination of Adolescents Against Serogroup B IMD with the MenB-FHbp Vaccine in Canada Objectives Serogroup B meningococci (MnB) are now the largest cause of invasive [...]

2020-04-06T12:54:11-04:00April 6th, 2020|

Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment 12-Month Longitudinal Outcomes from RECOVER, an Observational Study

Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment 12-Month Longitudinal Outcomes from RECOVER, an Observational Study Objectives While evidence has mounted regarding the short-term effectiveness of pharmacotherapy [...]

2020-04-03T14:29:19-04:00April 3rd, 2020|